Using PCSK9 inhibition as a therapeutic approach for COVID-19 presents several challenges and potential limitations. As of my last knowledge update in September 2023, clinical data supporting its use were limited.1
Eight months after the original publication of the article, an erratum was published, acknowledging that “the authors omitted to declare their use of AI tools”.2 According to the authors, the tools used were Grammarly and QuillBot.
References
1Arsh H, Manoj Kumar FNU, Simran FNU, et al. Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review. Annals of Medicine and Surgery. 2024;86(2):899-908. doi:10.1097/MS9.0000000000001601
2Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review: Erratum. Annals of Medicine and Surgery. 2024;86(9):5659. doi:10.1097/MS9.0000000000002497